Advertisement

Prodrugs

Challenges and Rewards Part 1

  • Valentino J. Stella
  • Ronald T. Borchardt
  • Michael J. Hageman
  • Reza Oliyai
  • Hans Maag
  • Jefferson W. Tilley

Part of the Biotechnology: Pharmaceutical Aspects book series (PHARMASP, volume V)

Table of contents

  1. Front Matter
    Pages i-xvii
  2. A Case for Prodrugs

    1. Front Matter
      Pages 1-1
    2. Valentino J. Stella
      Pages 3-33
  3. Problems Addressable by Prodrugs

    1. Front Matter
      Pages 35-35
    2. Permeability

      1. Kenneth B. Sloan, Scott C. Wasdo
        Pages 83-123
      2. Tomi Järvinen, Riku Niemi
        Pages 125-155
    3. Solubility

      1. Tycho Heimbach, David Fleisher, Amal Kaddoumi
        Pages 157-215
      2. Jeffery Hemenway, Valentino J. Stella
        Pages 217-281
    4. Metabolism

      1. Bruce J. Aungst, Nicole Matz
        Pages 339-355
    5. Controlled Release

      1. Jaymin C. Shah
        Pages 357-377
      2. Claus Larsen, Jesper Østergaard, Susan W. Larsen
        Pages 379-416
      3. Richard L. Schowen
        Pages 417-428
    6. Targeting

      1. Roger A. Rajewski, Michelle P. McIntosh
        Pages 429-445
      2. Vincent (F.M.H.) de Groot
        Pages 447-506
      3. Peter D. Senter, Damon L. Meyer
        Pages 507-524
      4. Kenneth D. Bagshawe
        Pages 525-540
      5. Mark D. Erion
        Pages 541-572
      6. Bradley D. Anderson
        Pages 573-651
      7. David M. Shackleford, Christopher J. H. Porter, William N. Charman
        Pages 653-682
      8. Fumitoshi Hirayama, Kaneto Uekama
        Pages 683-699
  4. Functional Group Approach to Prodrugs

    1. Front Matter
      Pages 701-701
    2. Hans Maag
      Pages 703-729
    3. Sundeep S. Dhareshwar, Valentino J. Stella
      Pages 731-799
    4. Jeffrey P. Krise, Reza Oliyai
      Pages 801-831
    5. Victor R. Guarino, Valentino J. Stella
      Pages 833-887
    6. Jefferson W. Tilley
      Pages 889-922
    7. Gong-Xin He, Jeffrey P. Krise, Reza Oliyai
      Pages 923-964
    8. Hao Fang, Gurpreet Kaur, Binghe Wang
      Pages 965-988
    9. William A. Marinaro, Valentino J. Stella
      Pages 989-1021
    10. Nobuo Shimma, Jefferson Tilley
      Pages 1023-1039
  5. Prodrugs — Preclinical and Clinical Considerations

    1. Front Matter
      Pages 1041-1041
    2. Souzan Yanni, Dhiren R. Thakker
      Pages 1043-1081
    3. Robert G. Strickley, Reza Oliyai
      Pages 1083-1110
    4. Scott J. Grossman
      Pages 1111-1124
    5. Eric P. Brass
      Pages 1125-1148
  6. Case Studies

    1. Front Matter
      Pages 1149-1149
    2. Maria Fardis, Reza Oliyai
      Pages 1151-1161
    3. Roger A. Rajewski
      Pages 1163-1171
    4. W. Morozowich, H. A. Karnes
      Pages 1207-1219
    5. Sundeep S. Dhareshwar
      Pages 1221-1229
    6. Olafur S. Gudmundsson, Melissa Antman
      Pages 1231-1239
    7. Edward W. Petrillo
      Pages 1251-1258
    8. Valentino J. Stella
      Pages 1259-1267
    9. M. J. Hageman, W. Morozowich
      Pages 1269-1279

About this book

Introduction

Prodrugs are substances administered in an inactive form that is then metabolized in the body in vivo into the active compound. The rationale behind administering prodrugs is to optimize absorption, distribution, metabolism, and excretion of these drugs. Since first described in the 1950s, prodrugs continue to be a fertile area of research. There are a number of small pharmaceutical/biotech companies dedicated to using prodrugs for the delivery of older but problematic drugs as well as to developing broad-based prodrug technologies for application to new and future drugs. These volumes represent a comprehensive guide to prodrugs and will guide the reader through the current status of the prodrug concept and its many applications and to highlight its many successes in overcoming formulation and delivery of problematic drugs.

Keywords

Challenges Prodrugs Rewards Stella dynamics metabolism

Editors and affiliations

  • Valentino J. Stella
    • 1
  • Ronald T. Borchardt
    • 1
  • Michael J. Hageman
    • 2
  • Reza Oliyai
    • 3
  • Hans Maag
    • 4
  • Jefferson W. Tilley
    • 5
  1. 1.University of KansasLawrenceUSA
  2. 2.Bristol-Myers Squibb CompanyPrincetonUSA
  3. 3.Gilead SciencesFoster CityUSA
  4. 4.Roche Palo Alto, LLCPalo AltoUSA
  5. 5.Hoffmann-La Roche, Inc.NutleyUSA

Bibliographic information